Combination HIV prevention reduces new infections by 42 percent in Ugandan district

NIH-supported study provides evidence for implementing approach broadly.

A study published today in the New England Journal of Medicine provides real-world evidence that implementing a combination of proven HIV prevention measures across communities can substantially reduce new HIV infections in a population.

Investigators found that HIV incidence dropped by 42 percent among nearly 18,000 people in Rakai District, Uganda, during a seven-year period in which the rates of HIV treatment and voluntary medical male circumcision increased significantly.

The HIV prevention strategy whose impact was observed in the study is based on earlier findings by the National Institutes of Health and others demonstrating the protective effect of voluntary medical male circumcision for HIV-uninfected men and of HIV-suppressing antiretroviral therapy (ART) for halting sexual transmission of the virus to uninfected partners. The strategy is also based on studies showing that changes in sexual behavior, such as having only one sexual partner, can help prevent HIV infection….

(Full Article)

FDA Approves First Two-Drug Regimen for Certain Patients with HIV

November 21, 2017 – the U.S. Food and Drug Administration approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1) instead of three or more drugs included in standard HIV treatment. Juluca is a fixed-dose tablet containing two previously approved drugs (dolutegravir and rilpivirine) to treat adults with HIV-1 infections whose virus is currently suppressed on a stable regimen for at least six months, with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca.

“Limiting the number of drugs in any HIV treatment regimen can help reduce toxicity for patients,” said Debra Birnkrant, M.D., director of the Division of Antiviral Products in the FDA’s Center for Drug Evaluation and Research….

(Full Article)

Durable End to the HIV/AIDS Pandemic Likely Will Require an HIV Vaccine

Despite remarkable gains in the treatment and prevention of HIV infection, development of an effective HIV vaccine likely will be necessary to achieve a durable end to the HIV/AIDS pandemic, according to a new commentary from Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Theoretically, effective global implementation of existing HIV treatment and prevention tools could end the HIV/AIDS pandemic. Antiretroviral therapy that suppresses HIV both benefits the health of those living with HIV and prevents viral transmission to their HIV-negative sexual partners. Additionally, strategies such as pre-exposure prophylaxis (PrEP) can effectively prevent HIV acquisition among people at high risk for infection.

(Full article)

UCLA Receives $5 Million Grant for Sharing Research on AIDS and Substance Abuse

The National Institute on Drug Abuse has awarded $5 million to researchers at UCLA Fielding School of Public Health to develop a resource and data center for millions of pieces of research, lab samples, statistics and other data aimed at boosting research into the effects of substance abuse on HIV/AIDS.

The five-year grant, called Collaborating Consortium of Cohorts Producing NIDA Opportunities, will connect groups of investigators with National Institute on Drug Abuse-funded research and data ranging from state-of-the-art bioinformatics to laboratory specimens, said Dr. Pamina Gorbach, professor of epidemiology at the UCLA Fielding School of Public Health and the principal investigator on the project.

Read the full story by clicking this link or visitng https://www.c3pno.org/

Covered California Announces Lower Prices for Most Enrollees in 2018 as Open Enrollment Approaches

  • Open enrollment begins Nov. 1 and runs through Jan. 31 — twice as long as the federal open-enrollment period.
  • New data on affordability shows that what 1.1 million subsidized consumers pay for their coverage will decrease by an average of 1.5 percent in 2018.
  • Consumers in the individual market who do not receive subsidies will pay an average of $115 per month less than in 2017 thanks to California’s healthy risk mix.
  • A $111 million investment in marketing and outreach includes new statewide multi-cultural, multi-lingual television ads delivering the message that “Life can change in an instant.”
  • Newly designed “responsive” website and provider search tools will make shopping easier than ever before.
  • Covered California will promote the beginning of open enrollment with a 22-stop bus tour visiting 19 cities throughout California, including locations where murals will be painted to attract attention to enrollment locations and promote health.

SACRAMENTO, Calif. — Covered California will kick off open enrollment Wednesday with the launch of a new comprehensive marketing and outreach campaign as well as upgrades to the consumer shopping experience for those seeking health insurance.

“While we know there is confusion because of the uncertainty in Washington, we want people to know that Covered California is rock solid,” said Peter V. Lee, executive director of Covered California. “We’re offering stability, choice and affordable options in 2018 in the face of uncertainty in much of the country.”

Open enrollment is the one time of year when anyone who needs health insurance can enroll without needing to meet special qualifying conditions. Covered California’s open-enrollment period will continue for three months, while open enrollment in 42 other states will end on Dec. 15.

(Full article)

HRSA awards $2.36 billion in grants to help Americans access HIV/AIDS care and medications

October 18, 2017 – The Health Resources and Services Administration (HRSA) announced today approximately $2.36 billion in Ryan White HIV/AIDS Program grants awarded to cities, counties, states, and local community-based organizations in fiscal year (FY) 2017. This funding supports a comprehensive system of HIV primary medical care, medication, and essential support services to more than half a million people living with HIV in the United States.

“The Ryan White HIV/AIDS Program plays a critical role in the United States’ public health response to HIV,” said HRSA Administrator George Sigounas, MS, Ph.D. “These grants will ensure that the most vulnerable Americans living with HIV/AIDS will have access to the necessary care and treatment needed to improve their health quality and medical outcomes.”

HRSA oversees the Ryan White HIV/AIDS Program, which is a patient-centered system that provides care and treatment services to low income people living with HIV to improve health outcomes and reduce HIV transmission among hard to reach populations. The program serves more than 50 percent of people living with diagnosed HIV infection in the United States.

(Full article)

SAMHSA Awards $166 Million for HIV Prevention and Treatment

October 5, 2017 – The Substance Abuse and Mental Health Services Administration (SAMHSA) has awarded grants totaling $166 million over five years through its Targeted Capacity Expansion-HIV (TCE-HIV) Program and its Prevention Navigator Program. The grant funding will be used to prevent HIV among high-risk populations and to treat co-occurring behavioral health disorders and HIV.

Grantees will use the funds for activities such as outreach, screening, prevention and treatment. “Our efforts in vulnerable communities have shown us that prevention works,” said Dr. Elinore McCance-Katz, Assistant Secretary for Mental Health and Substance Use. “This funding will be used to increase access to a range of services important to prevention, recovery and healthy living.”

(Full Article)

Stimulant Use: Harm Reduction, Treatment, and Future Directions Conference

September 25, 2017 – the Drug Policy Alliance (DPA) hosted the “Stimulant Use: Harm Reduction, Treatment, and Future Directions” conference to engage participants in dialogue about stimulant use. Within the walls of the Japanese American National Museum in downtown Los Angeles, harm reduction providers, social service providers, researchers, policy makers, the LGBTQ community, and people who use stimulants explored the complexities of stimulant use through a series of panels.

CHIPTS Center Director and CBAM Executive Director, Dr. Steven Shoptaw PhD, gave the closing remarks at the conference after a day full of rich conversation surrounding stimulant use.

You can read more on the report here and download the full report of the conference here:  Stimulant Use: Harm Reduction, Treatment, and Future Directions Conference - Report

Fogarty Training Program Workshop in Hanoi – Community-Based Intervention Studies

2017-09-05_23-37-02September 8, 2017, Hanoi, Vietnam — During September 6th-8th, 2017, Faculty and researchers from academic institutions in Vietnam, researches from local NGOs, Ministry of Health Program Managers, Graduate students of Hanoi Medical University, and Fellows of the Vietnam Fogarty Training Program gathered together for a workshop series on “Community-Based Intervention Study in HIV/AIDS and Substance Abuse.”

The purpose was to improve understanding of various aspects of community-based intervention studies to identify and prevent and support treatment and care of HIV infections and substance abuse disorders and to appreciate challenges of designing and conducting a community-based intervention, and developing together.2017-09-06_20-03-34

Workshops ranged in a variety of topics such as Development and Delivery of Behavioral Interventions presented by CHIPTS Dr. Li Li who also presented Intervention Studies Involved Service Providers, Behavioral Interventions for Substance Abuse in the Setting of HIV by Dr. Professor Steve Shoptaw, and more.

2017-09-05_23-37-41Meanwhile Dr. Shoptaw also spoke on the Medications for Substance Abuse in the Setting of HIV while another CHIPTS faculty member, Dr. Chunqing Lin presented on An Overview of Implementation Science in Healthcare.

The conference concluded with feedback from the UCLA faculty for the attendees who had collaborated to create preliminary concepts on community-based interventions that are relevant for the context of Vietnam.

For more information on the Fogarty Training Program, its goals, and its global locations, check out their page under the Education tab!